NMTC NEUROONE MEDICAL TECHNOLOGIES CORP

NeuroOne® to Present at the ThinkEquity Conference on October 19, 2023

NeuroOne® to Present at the ThinkEquity Conference on October 19, 2023

EDEN PRAIRIE, Minn., Oct. 13, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that CFO Ron McClurg will present at the ThinkEquity Conference in New York on Thursday, October 19, 2023.

Conference details:

Presentation Date:Thursday, October 19, 2023
Presentation Time*:9:00 am ET
Location:Mandarin Oriental Hotel, New York City
Registration:Available on the .
1x1 meetings:Requests available upon registration.
  

*The presentation time may be subject to change. Attendees may refer to the program agenda for more information.

About NeuroOne

NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit . 

Caution: Federal law restricts this device to sale by or on the order of a physician.

Contact:

800-631-4030



EN
13/10/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NEUROONE MEDICAL TECHNOLOGIES CORP

 PRESS RELEASE

NeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; G...

NeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6% Filed 510(k)Submission with FDA for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain Ahead of Schedule Company Fully Funded Through at Least Fiscal Year 2026 Following Oversubscribed $8.2 Million Capital Raise EDEN PRAIRIE, Minn., May 13, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological di...

 PRESS RELEASE

NeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medic...

NeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medical Advisor Significant Neurological Expertise to Help Drive Clinical Development Strategy and Growth with New Technologies EDEN PRAIRIE, Minn., May 12, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced it has appointed Parag G. Patil, M.D., Ph.D., as Chief Medical Advisor (CMA), after serving on the company...

 PRESS RELEASE

NeuroOne® to Report Second Quarter Fiscal Year 2025 Financial Results ...

NeuroOne® to Report Second Quarter Fiscal Year 2025 Financial Results on Tuesday, May 13 at 8:30 a.m. Eastern Time EDEN PRAIRIE, Minn., May 01, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal second quarter ended March 31, 2025, before market open on May 13, 2025. Management will host an investor conference call and webcast at 8:30 a.m. Eastern...

 PRESS RELEASE

NeuroOne® Completes FDA Submission for the OneRF® Trigeminal Nerve Abl...

NeuroOne® Completes FDA Submission for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain Multi-Contact Probe Provides Alternative to Pharmaceutical and Invasive Surgical Treatments Submission Completed Earlier Than Anticipated EDEN PRAIRIE, Minn., April 23, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has filed its 510(k) submission to the FDA for trigeminal nerve ablati...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch